Download Image
    
Share
  
Post
Efmarodocokin alfa for COVID-19
1 study with 266 patients
Hospital Icon Control
Hospital Icon Efmarodocokin Alfa Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Efmarodocokin alfa studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -15% Mortality -15% RCTs -15% Late -15% Favorsefmarodocokin alfa Favorscontrol
Recent:
Waters.
Nov 14
2022
 Waters et al., Critical Care Medicine, doi:10.1097/CCM.0000000000005716 Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial
15% higher mortality (p=0.67) and 13% improved recovery (p=0.35). RCT 396 hospitalized patients with severe COVID-19 pneumonia showing no significant difference in time to recovery with astegolimab (IL-33 receptor blocker) or efmarodocokin alfa (IL-22 pathway activator). Median time to recovery was 11 d..